Sam Finn, a senior research associate at Zymo Research working with the Oncology Diagnostic Team, helped to host this interactive game booth at the “BioFestival” on Tuesday.

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

In this article, we are going to take a look at where Blueprint Medical (NASDAQ ... The datasets, which include one oral presentation and three poster presentations, will be reported Over the ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Plastic is the most prevalent marine pollutant, and plastic surfaces are the fastest growing habitat in the ocean. Researchers at the University of Hawai'i (UH) at Mānoa have recently discovered ...

Imagine a future where parents can choose their baby's traits. In-vitro gametogenesis (IVG) is making this closer to reality by creating sperm and eggs in a lab. While this offers hope for ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...